Phase 1/2Enrolling by invitation

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

ImmuneNet: Quantum-Synaptic Immunotherapy Mapping

Sponsor
Truway Health, Inc. (Industry)
Enrollment
120 planned
Conditions
Systemic Lupus Erythematosus; Rheumatoid Arthritis; Multiple Sclerosis; Autoimmune Diseases; Chronic Inflammatory Syndromes; Immune Dysregulation
Interventions
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR); Sham Resonance Device (Inactive Control); Low-Dose Naltrexone (LDN)
Ages
children, adults, older adults
Registry
NCT07221565

Full record on ClinicalTrials.gov

From the registry

The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in…

Primary outcomes

  • Change in Autoimmune Flare Frequency

History

  1. Primary completion expected

  2. Last registry update

  3. Registered

  4. Started